Japan’s Eisai Looks To MGI Pharma Acquisition For Growth
This article was originally published in PharmAsia News
Executive Summary
Japan's Eisai is looking to expanded sales of MGI Pharma in its home country of the United States for the acquiring company's own improvement. MGI's CEO Lonnie Moulder expects Eisai's acquisition to be symbiotic, with Eisai's sales staff combining with MGI's to put 900 representatives on the ground in the United States. Eisai looks to the MGI tie to counteract a reduction it faces in its own drug pipeline as patents on key products expire. Other Japanese drug makers have chosen to merge with each other. (Click here for more - a subscription may be required